Evidence map›Paper›PMID 28812539›Full record

ArticleBMC genomics2017

Investigating Ebola virus pathogenicity using molecular dynamics.

Morena Pappalardo, Francesca Collu, James Macpherson, Martin Michaelis, Franca Fraternali, Mark N Wass

Open access · goldAbstract read
In one paragraph

Article in BMC genomics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Morena PappalardoSchool of Biosciences, University of Kent, Kent, UK.
Francesca ColluRandall Division of Cell and Molecular Biophysics King's College London, London, UK.
James MacphersonRandall Division of Cell and Molecular Biophysics King's College London, London, UK.
Martin MichaelisSchool of Biosciences, University of Kent, Kent, UK.
Franca FraternaliRandall Division of Cell and Molecular Biophysics King's College London, London, UK. f.fraternali@kcl.ac.uk.
Mark N WassSchool of Biosciences, University of Kent, Kent, UK. m.n.wass@kent.ac.uk.
King's College London · GBUniversity of Kent · GB

Funding

Medical Research Council MR/L01257X/1
6 · The paper itself

Abstract

backgroundEbolaviruses have been known to cause deadly disease in humans for 40 years and have recently been demonstrated in West Africa to be able to cause large outbreaks. Four Ebolavirus species cause severe disease associated with high mortality in humans. Reston viruses are the only Ebolaviruses that do not cause disease in humans. Conserved amino acid changes in the Reston virus protein VP24 compared to VP24 of other Ebolaviruses have been suggested to alter VP24 binding to host cell karyopherins resulting in impaired inhibition of interferon signalling, which may explain the difference in human pathogenicity. Here we used protein structural analysis and molecular dynamics to further elucidate the interaction between VP24 and KPNA5.

resultsAs a control experiment, we compared the interaction of wild-type and R137A-mutant (known to affect KPNA5 binding) Ebola virus VP24 with KPNA5. Results confirmed that the R137A mutation weakens direct VP24-KPNA5 binding and enables water molecules to penetrate at the interface. Similarly, Reston virus VP24 displayed a weaker interaction with KPNA5 than Ebola virus VP24, which is likely to reduce the ability of Reston virus VP24 to prevent host cell interferon signalling.

conclusionOur results provide novel molecular detail on the interaction of Reston virus VP24 and Ebola virus VP24 with human KPNA5. The results indicate a weaker interaction of Reston virus VP24 with KPNA5 than Ebola virus VP24, which is probably associated with a decreased ability to interfere with the host cell interferon response. Hence, our study provides further evidence that VP24 is a key player in determining Ebolavirus pathogenicity.

Indexed as

Molecular Dynamics Simulationalpha KaryopherinsEbolavirusHemorrhagic Fever, EbolaHumansProtein ConformationViral Proteinsalpha KaryopherinsKPNA5 protein, humanViral ProteinsVP24 protein, Ebola virusEbolaMolecular dynamicsPathogenicityProtein structureVirology

Identifiers

PMID28812539
PMCPMC5558184
OpenAlexW2625387716

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.